Back to search

Article

Tolerability of Eribulin and Correlation Between Polymorphisms and Neuropathy in an Unselected Population of Female Patients with Metastatic Breast Cancer: Results of The Multicenter, Single Arm, Phase IV PAINTER Study

2022-02-07

Abstract excerpt

BACKGROUND Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses on prolonging patients (pts) overall survival (OS) and improving their quality of life. eribulin is a microtubule inhibitor that increases OS in pre-treated MBC pts. Its common adverse events (AEs) are asthenia, neutropenia and peripheral neuropathy (PN). METHODS The PAINTER is a single arm, phase IV study, aimed at surveyi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e2d417f2-5af3-55ff-8e55-95dbb3fe2ae9
DOI
10.21203/rs.3.rs-1321818/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Tolerability of Eribulin and Correlation Between Polymorphisms and Neuropathy in an Unselected Population of Female Patients with Metastatic Breast Cancer: Results of The Multicenter, Single Arm, Phase IV PAINTER StudyDOI 10.21203/rs.3.rs-1321818/v1
Real-world data of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer centerSemantic proximity
Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study.Semantic proximity
Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.Semantic proximity
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerSemantic proximity
Prognostic Role of Tumor Subtype and Germline BRCA Mutation in Advanced Breast Cancer Patients Treated with Palbociclib Plus Endocrine TherapySemantic proximity
The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity
Polymorphism of <em>CYP3A4</em> and <em>ABCB1</em> genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxelSemantic proximity
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.Semantic proximity
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.Semantic proximity
Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.Semantic proximity
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.Semantic proximity
Efficacy and Safety of the use of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico del Nord Ovest) StudySemantic proximity
Select a neighboring publication to make it the new centre.